Literature DB >> 10948026

Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database.

R D Farmer1, T J Williams, E L Simpson, A L Nightingale.   

Abstract

OBJECTIVE: To compare the incidence of venous thromboembolism among women taking combined oral contraceptives before and after the October 1995 pill scare.
DESIGN: Analysis of General Practice Research Database.
SETTING: United Kingdom, January 1993 to December 1998.
SUBJECTS: Women aged 15-49 taking combined oral contraceptives. MAIN OUTCOME MEASURES: Incidence of venous thromboembolism.
RESULTS: Use of so called "third generation" combined oral contraceptives fell from 53% during January 1993 to October 1995 to 14% during November 1995 to December 1998. There was no significant change in the incidence of venous thromboembolism between the two periods after age was adjusted for (incidence ratio 1.04, 95% confidence interval 0.78 to 1.39).
CONCLUSIONS: The findings are not compatible with the assertion that third generation oral contraceptives are associated with a twofold increase in risk of venous thromboembolism compared with older progestogens.

Entities:  

Keywords:  Contraception; Contraceptive Methods; Developed Countries; Diseases; Embolism; Europe; Family Planning; Longitudinal Studies; Northern Europe; Oral Contraceptives; Oral Contraceptives, Combined; Research Methodology; Research Report; Studies; Thromboembolism; United Kingdom; Vascular Diseases

Mesh:

Substances:

Year:  2000        PMID: 10948026      PMCID: PMC27461          DOI: 10.1136/bmj.321.7259.477

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  15 in total

1.  Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95.

Authors:  L Mellemkjaer; H T Sørensen; L Dreyer; J Olsen; J H Olsen
Journal:  BMJ       Date:  1999-09-25

2.  DoH seems to have underestimated incidence of venous thromboembolism in users of combined oral contraceptives.

Authors:  R A Lawrenson; A Whalley; E Simpson; R D Farmer
Journal:  BMJ       Date:  1999-08-07

3.  Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.

Authors:  H Jick; S S Jick; L E Derby
Journal:  BMJ       Date:  1991-03-30

4.  Oral contraceptives and fatal pulmonary embolism.

Authors:  L Parkin; D C Skegg; M Wilson; G P Herbison; C Paul
Journal:  Lancet       Date:  2000-06-17       Impact factor: 79.321

5.  Validation of the diagnosis of venous thromboembolism in general practice database studies.

Authors:  R Lawrenson; J C Todd; G M Leydon; T J Williams; R D Farmer
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

6.  A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.

Authors:  R D Farmer; R A Lawrenson; J C Todd; T J Williams; K D MacRae; F Tyrer; G M Leydon
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

7.  Population-based study of risk of venous thromboembolism associated with various oral contraceptives.

Authors:  R D Farmer; R A Lawrenson; C R Thompson; J G Kennedy; I R Hambleton
Journal:  Lancet       Date:  1997-01-11       Impact factor: 79.321

8.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

9.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

10.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  W O Spitzer; M A Lewis; L A Heinemann; M Thorogood; K D MacRae
Journal:  BMJ       Date:  1996-01-13
View more
  15 in total

1.  Pitfalls of pharmacoepidemiology.

Authors:  J A Kaye; C Vasilakis-Scaramozza; S S Jick; H Jick
Journal:  BMJ       Date:  2000-12-16

2.  Pitfalls of pharmacoepidemiology.

Authors:  R Farmer; T Williams; A Nightingale
Journal:  BMJ       Date:  2000-11-25

3.  Pitfalls of pharmacoepidemiology.

Authors:  D C Skegg
Journal:  BMJ       Date:  2000-11-11

Review 4.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

5.  Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis.

Authors:  Christopher J Weatherburn; Bruce Guthrie; Tobias Dreischulte; Daniel R Morales
Journal:  Br J Clin Pharmacol       Date:  2019-12-16       Impact factor: 4.335

Review 6.  A pathway to improved prospective observational post-authorization safety studies.

Authors:  Victor A Kiri
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

Review 7.  Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?

Authors:  James Drife
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Hormonal contraception and thrombotic risk: a multidisciplinary approach.

Authors:  Cameron C Trenor; Richard J Chung; Alan D Michelson; Ellis J Neufeld; Catherine M Gordon; Marc R Laufer; S Jean Emans
Journal:  Pediatrics       Date:  2011-01-03       Impact factor: 7.124

9.  Attitudes towards drugs--a survey in the general population.

Authors:  D Isacson; K Bingefors
Journal:  Pharm World Sci       Date:  2002-06

10.  Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.

Authors:  Aukje K Mantel-Teeuwisse; Olaf H Klungel; Toine C G Egberts; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.